Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 44,580 shares at $70.11 ($3.1M) on 2024-02-26, disclosed to the SEC on 2024-02-27.
Scheduled sale ($3.1M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.39 | 600 | $41K | 1.3% |
| 2 | $69.45 | 9,528 | $662K | 21.3% |
| 3 | $69.45 | 9,528 | $662K | 21.3% |
| 4 | $70.11 | 12,462 | $874K | 28.1% |
| 5 | $70.11 | 12,462 | $874K | 28.1% |
| Total | $69.80 avg | 44,580 |
| $3.1M |
| 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |